Selected article for: "mortality rate and onset symptom"

Author: Richier, Q; Jachiet, V; Bonnemains, V; Plaçais, L; Abisror, N; Garnier, M; Pacanowski, J; Dhote, R; Hinchschberger, O; Michel, M; Bienvenu, B; Comarmond, C; Lacombe, K; Mekinian, A
Title: Tocilizumab and COVID-19: timing of administration assessment
  • Cord-id: 4vj8mrf9
  • Document date: 2021_6_29
  • ID: 4vj8mrf9
    Snippet: Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no association between the timing of injection after symptom onset and the efficacy of TCZ on mortality. We then investigated whether the oxygen level at the time of TCZ injection impacted the mortality
    Document: Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no association between the timing of injection after symptom onset and the efficacy of TCZ on mortality. We then investigated whether the oxygen level at the time of TCZ injection impacted the mortality rate. Our study finally suggested that TCZ could be less effective when oxygen requirement is >11 L/min and we hypothesized that earlier administration could be associated with better outcome. However, randomized clinical trials are required to confirm this hypothesis.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and logistic analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and logistic analysis multivariate: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and logistic multivariate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung involvement severity: 1, 2, 3
    • acute phase and logistic analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute phase and logistic analysis multivariate: 1, 2, 3, 4
    • acute phase and logistic multivariate: 1, 2, 3, 4, 5, 6, 7
    • acute phase and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute phase and lung involvement severity: 1
    • administration timing and logistic analysis: 1, 2
    • logistic analysis and low oxygen requirement: 1
    • logistic analysis and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8
    • logistic analysis multivariate and lung involvement: 1, 2, 3
    • logistic multivariate and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • logistic multivariate and lung involvement severity: 1